Find stats on top websites

Business and Product Insights

Product Portfolio

Axonics External Trial System

Axonics Sacral Neuromodulation System

Axonics Sacral Neuromodulation MRI Device

Axonics, Inc. Key Value Propositions

Axonics' key value proposition is providing a 'TRULY Recharge-Free SNM System' that offers long-term, effective relief from bladder and bowel dysfunction. This innovation significantly improves patient convenience and quality of life by eliminating the need for frequent device recharging.

Recharge-Free SNM System
Bladder/Bowel Dysfunction Relief
Improved Quality of Life
Advanced Treatment Option

Axonics, Inc. Brand Positioning

Axonics positions itself as the leader in patient-friendly Sacral Neuromodulation, offering the only truly recharge-free SNM system for bladder and bowel dysfunction. They empower patients with lasting relief and improved quality of life.

Top Competitors

1

Medtronic InterStim

2

Boston Scientific (broader urology solutions)

3

Nevro Corp.

Customer Sentiments

Customer sentiment appears to be positive and hopeful, as patients are actively seeking effective, long-term solutions after failed traditional treatments. They are motivated to engage and qualify for Axonics' advanced therapy, indicating a high level of trust and interest.

Actionable Insights

To reinforce its brand position, Axonics should continue emphasizing the 'truly recharge-free' benefit in all patient-facing communications and leverage patient testimonials showcasing sustained relief.

Products and Features

Axonics External Trial System - Product Description

The Axonics® External Trial System is a diagnostic and preliminary assessment tool designed to allow healthcare providers to evaluate the effectiveness of sacral neuromodulation (SNM) therapy for patients experiencing urinary or bowel dysfunction. This system enables patients to trial the therapy externally, without undergoing a full surgical implant, to assess symptom improvement before committing to the permanent procedure. It facilitates a reversible and non-invasive initial assessment, providing valuable insights into potential patient response to SNM.

Pros

  • It allows patients to experience the therapy's benefits and assess symptom improvement prior to a permanent surgical implant
  • This reduces the commitment and risk for patients, potentially increasing their willingness to consider SNM therapy
  • The system provides valuable diagnostic information to healthcare providers, helping them determine patient suitability for long-term sacral neuromodulation.

Cons

  • As an external system, it may have limitations in mimicking the exact long-term experience of a fully implanted device
  • Patients might find the external components cumbersome or inconvenient during the trial period
  • The trial system itself incurs costs and resources, even if a patient does not proceed with the full implant.

Alternatives

  • Medtronic's InterStim™ system also offers a trial period for sacral neuromodulation, serving as a direct competitor in this space
  • Other alternatives for bladder and bowel control may include oral medications, lifestyle modifications, or more invasive surgical procedures like Botox injections into the bladder
  • Non-invasive physical therapies and biofeedback are also used for managing these conditions, offering less intrusive initial options.

Company Updates

Latest Events at Axonics, Inc.

Axonics® Therapy | Get Your Bladder Back

Axonics® System is an FDA-approved, clinically proven Sacral Neuromodulation solution for the treatment of urinary and bowel dysfunction.

View source

Boston Scientific Announces Agreement to Acquire Axonics, Inc.

Jan 8, 2024 ... Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue. https://ir.axonics.com/news-releases. SOURCE Boston Scientific Corporation.

View source

Axonics® System for Sacral Neuromodulation Overview

Axonics SNM Systems deliver constant current stimulation to help maintain the right amount of therapy and reduce the need for patients to make adjustments.

View source

Boston Scientific Investor Relations

Investors · Recent Quarterly Results · Boston Scientific Conference Call Discussing Second Quarter Financial Results · Annual Results and Proxy Statements.

View source

Transform Your Ideas into Action in Minutes with WaxWing

Sign up now and unleash the power of AI for your business growth